Russian healer heals prostatitis, impotence, adenoma

I already wrote about chlamydia and chlamydia. In addition, it is important to know the symptoms are infected with chlamydia. Nongonococcal uretritis (NGU) is an infection caused by Chlamydia trachomatis and other organisms, but not the causative agent of gonorrhea. Half of all cases of NGU are due to an infection of Chlamydiae. Worldwide NGU is one of the most common sexually transmitted diseases (STD) in men.
Symptoms of NGU caused by Chlamydiae are manifested after an incubation period that lasts from 5 to 30 days. In men, the initial focus of chlamydial infection is the mucous membrane of the urethra. Chlamydia is most often seen in men as a slight inflammation of the urethra, which is chronic and lasts at least several months. NGU often develops minor symptoms. Within 1-6 weeks after you have become infected with Nongonococcal Uretritis , the following symptoms may appear:
Pain on urinating, especially in the first time in the morning
Discharge from the penis
Redness and discomfort at the opening of the urethra.
In men Nongonococcal Uretritis can lead to various complications. Symptoms of chlamydial epididymo-orchitis (inflammation of testes and epididymides) develop after Chlamydiae have spread to the testes and epididymides. The scrotum becomes sharply painful on palpation, swelling, hot to the touch. Chronic unilateral epididymo-orchitis and prostatitis are accompanied by disorders of sexual potency and spermiogram.
Chlamydial prostatitis (inflammation of the prostate gland) is a frequent complication of Nongonococcal Uretritis. Patients complain of discharge from the urethra, itching, recurrent pain in the groin, scrotum, and sacrum. Chlamydial infection can trigger an immune response that leads to inflammation of joints (reactive arthritis).
If your doctor suspects that you show the symptoms of Nongonococcal Uretritis, he or she takes a swab from your urethra and a urine sample to check for the presence of Chlamidiae. Tests for the other sexually transmitted diseases may carry out at the same time.

This message is about Alexander Zass (Iron Samson as it was called in the West) which I have repeatedly blogged (Iron Samson – the strongest man of the Earth). I trained in his system. Let the strong man I did not (performance is slightly above average), but it worked the system.
Recently found an old video of Alexander Zass, or rather black-and-white newsreels. Watch and make conclusions. In the video, he is older than 50 years, but apparently that is very strong. English origin newsreel Alexander Zass quite logical. Zass lived and died in England. In the USSR, his name was virtually a taboo subject and there were few people know. Only in the late 1980s, the country learned about the Iron Samson after publishing an article by Yuri Shaposhnikov in the journal «Science of Life.» By the way this magazine I have read all of it.

Chlamydia is a sexually transmitted infection (STD), that caused by Chlamydia trachomatis which is a unique organism. Chlamydiae live inside the living cell as viruses, but their structure is similar to the bacteria. Because of the dual nature of Сhlamydiae and the ability to parasitize intracellularly chlamydia is extremely difficult to cure.
According to WHO, chlamydia is one of the most common STD worldwide. Every year almost 90 million people infected with chlamydia in the world.

The cycle of Chlamydia trachomatis continues for two days, but in that period they are very sensitive to antibiotics, chemotherapy, ultraviolet rays, and high temperatures.
Chlamydial infection is sexually transmitted. After casual sex chlamydia detected in 50% of women and 60% of men, although a single contact with a patient with chlamydia does not always lead to infection in the partner. The mechanism of transmission of chlamydia is realized with genital-genital, genital-anal and genital-oral sex. Persons aged 17 to 35 years are in the risk group of reproductive tract infections caused by chlamydia. Unsexual route of transmission of chlamydial infection (through infected arms, clothes) considered as irrelevant.

Chlamydia is the cause of diseases of the urogenital tract: cystitis, urethritis, cervicitis, erosion, vulvovaginitis, prostatitis, endometritis, epididymitis, coleitis, orchitis, parauretritis, vulvitis, salpingitis, salpingo-oophoritis. Also chlamydial urogenital infection associated with diseases of eyes, joints, respiratory lesions. Chlamydia is also a frequent cause of arthritis, and even disorders of the cardiovascular system.

Bacterial prostatitis is a scourge on men’s health. However, ill prostatitis without leaving home. As follows from a British study
in nine out of ten homes towels are fraught with dangerous levels of bacteria that cause disorders of the gastrointestinal tract. The experts made ​​an interesting point: many people are more at risk of poison, using the towel, rather than eating in establishments catering.
The British Health Protection Agency specifically examined in restaurants kitchen towels and found: 56% of them contained E. coli and organisms that cause listeriosis. Analysis of 100 kitchen towels, which were used at home, showed even higher levels of dangerous bacteria – almost 90%. Therefore, experts recommend regularly washing towels and leave them next to the sink. Contact with E. coli in the body can and bacterial prostatitis.

The Daily Express reports that a “new treatment for prostate cancer has cut the risk of dying by half”. It said that “six months of the hormone therapy……is all that is needed”, and the benefits continue for 10 years.

The trial in question did not look at androgen deprivation therapy (ADT) alone. It provided either three or six months of ADT before and around the time that the men received radiotherapy (a schedule of delivery referred to as neoadjuvant therapy), and compared this with radiotherapy alone. It found that six months of neoadjuvant ADT reduced the chances of men dying from prostate cancer over 10 years of follow-up. But three months of neoadjuvant ADT only significantly improved some outcomes, though not deaths from prostate cancer.

The study used a robust design, and its results indicate that six months of ADT before radiotherapy is beneficial in men with locally advanced prostate cancer. However, as the study started more than a decade ago, it used a lower dose of radiation than is currently used, which may affect whether these findings can be generalised.

National Institute for Health and Clinical Excellence guidelines already suggest that men with locally advanced prostate cancer should be offered 3–6 months of this type of neoadjuvant therapy (luteinising hormone-releasing hormone agonist therapy) before and while receiving radiotherapy.
Where did the story come from?

The study was carried out by researchers from the University of Newcastle in Australia and other research centres in Australia and New Zealand. It was funded by the Australian Government National Health and Medical Research Council, Hunter Medical Research Institute, and the manufacturers of the two drugs used in the trial (AstraZeneca and Schering-Plough).

The study was published in the peer-reviewed medical journal The Lancet.

This story was covered by the DailyExpress, Daily Mail, and The Daily Telegraph. Although the reports generally convey the main findings of the trial, there are some potentially misleading statements.

The Daily Mail suggests that “just six months of the treatment could cure in many cases”, but as the study followed people for just 10 years, it is difficult to say how many of them will remain free of cancer in their lifetimes.

The Express suggests that this hormonal treatment is “all that is needed”, but it is actually given alongside radiotherapy. Also, it is not possible to say from the trial whether longer treatment would increase benefits further.

The Telegraph suggests that the hormonal therapy is given “before and after radiotherapy”, whereas it was given before, with a one-month overlap with the start of radiotherapy.
What kind of research was this?

This was a long-term (10-year) follow-up of a randomised controlled trial looking at the effectiveness of androgen deprivation therapy (ADT) given before radiotherapy for locally advanced prostate cancer. The earlier, five-year results of this trial (the Trans-Tasman Radiation Oncology Group [TROG] 96.01 trial) suggested that six months of ADT reduced metastases and deaths from prostate cancer.

This study design is the most appropriate way of testing whether a new or modified treatment is better than the current standard treatment, as it is the best way of ensuring that the only difference between the groups is the treatment received.
What did the research involve?

The researchers compared three treatments for locally advanced prostate cancer in 818 men aged 41 to 87 years old.
radiotherapy alone
three months of androgen deprivation therapy (ADT) plus radiotherapy
six months ADT plus radiotherapy

Participants were randomly assigned to receive one of these treatments and were then followed up for 10 years to observe their outcomes. This type of treatment, where ADT is delivered before and alongside radiotherapy, is called neoadjuvant androgen deprivation therapy (NADT). ADT can also be used for relapses after radiotherapy, though this was not studied in this trial.

Men who had other significant medical illnesses were not eligible to take part, nor men who had previous malignancies or metastases. NADT consisted of two drugs called goserelin (3.6mg given as an injection under the skin once a month) and flutamide (250mg pill given orally three times a day). The group who received three months of NADT started this treatment two months before radiation started. The group who received six months of NADT started this treatment five months before radiation started. All groups received radiation according to the same treatment schedule.

The researchers enrolled 818 men between 1996 and 2000. After 10 years of follow-up, 802 men were available for analysis. After they had received radiotherapy, the men had been assessed every four months for the first two years, then every six months for the next three years. After this, men with no signs of cancer were followed-up annually.

At each visit, the men had a digital rectal examination, and their serum PSA levels were measured (a biochemical marker that is used to monitor prostate cancer recurrence). Men who had signs or symptoms that their cancer might be returning had further investigations as appropriate, such as biopsies and CT scans. If prostate cancer did reoccur, their doctor could offer whatever treatment was appropriate.

The researchers were mainly interested in whether the treatment affected the proportion of men who died from prostate cancer or the proportion who died from any cause. They were also interested in the proportion of men whose PSA levels indicated progression of the disease, who had local progression of their prostate cancer, spread of their cancer elsewhere in the body (distant progression), or needed further treatment, and the length of time the men survived without any of these disease events.

In their analyses, the researchers took into account each participant’s age, initial level of PSA, and the stage of their cancer at the start of the study.
What were the basic results?

During follow-up, there were 334 deaths, of which 159 were due to prostate cancer. There were 33 deaths from prostate cancer in the six-month NADT plus radiotherapy group (11.4%). There were 56 deaths in the three-month NADT plus radiotherapy group (18.9%), and 70 deaths in the radiotherapy alone group (22.0%).

The researchers found that having six months of NADT before radiotherapy reduced the likelihood of men dying from prostate cancer during the 10 years of follow-up, but three months of NADT did not have this effect. The risk of death from prostate cancer during follow-up was 51% lower with six months of NADT plus radiotherapy than with radiotherapy alone (hazard ratio [HR] 0.49, 95% confidence interval [CI] 0.31 to 0.76).

Compared to men who received radiotherapy alone, men who received six months of NADT plus radiotherapy were also less likely to die from any cause during follow-up (HR 0.63, 95% CI 0.48 to 0.83), or to experience any disease progression event during follow-up (HR 0.51, 95% CI 0.42 to 0.61). Three months of NADT plus radiotherapy did not reduce the risk of death from any cause, or of distant progression of the disease compared with radiotherapy alone. But it did reduce the risk of local progression and the risk of having PSA levels that indicated progression of the disease.

Side effects of NADT were reported to be temporary and only occurred during the NADT treatment, not after. NADT did not appear to exacerbate the adverse effects associated with radiotherapy.
How did the researchers interpret the results?

The researchers concluded that “six months of neoadjuvant androgen deprivation combined radiotherapy is an effective treatment option for locally advanced prostate cancer”.
Conclusion

This long-term follow-up of the TROG 96.01 trial found that having six months of androgen deprivation therapy (goserelin plus flutamide) before radiotherapy reduces the 10-year risk of death among men with locally advanced prostate cancer. The study has a robust design, and it assessed important clinical outcomes – such as the risk of death from prostate cancer – rather than just intermediate outcomes, such as reductions in PSA levels that were the main beneficial outcomes in the previous five-year report of this trial.

One limitation noted by the authors is that the dose of radiotherapy used in their study (66 Gy), which was initiated over a decade ago, was low by modern standards. They say that this increase in radiation dose may have contributed to the improved progression-free survival in men with prostate cancer observed over time. This study cannot prove that NADT would be beneficial when added to a higher dose of radiation. However, this would seem likely, considering the size of the benefit from NADT. The authors also carried out some computer simulations suggesting that six months of ADT might still be beneficial in this context.

This study has helped to resolve some questions about the scheduling and duration of existing ADT treatments. It does not describe a new treatment as suggested by the press, but an alternative way of delivering existing therapy.
Information
This article was originally published by NHS Choices